Lorviqua 100 mg film-coated tablets
Sponsors
Centro Di Riferimento Oncologico Di Aviano, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Intergroupe Francophone De Cancerologie Thoracique
Conditions
ALK positive Non-Small Cell Lung CancerAdvanced ROS1-positive non-small cell lung cancerAdvanced solid tumorMultiple myelomaNon-Hodgkin lymphomaT-cell prolymphocytic leukemia
Phase 2
A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression on Lorlatinib
RecruitingCTIS2023-506714-43-00
Start: 2024-03-15Target: 45Updated: 2025-10-21
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
IFCT-2003 ALBATROS A phase II single-group assignment, multicenter study of efficacy and safety of lorlatinib monotherapy after failure of first-line tyrosine kinase inhibitor in patients with advanced ROS1-positive non-small cell lung cancer
Active, not recruitingCTIS2024-512028-12-00
Start: 2021-03-19Target: 84Updated: 2025-09-17